Himalaya: Listen. Learn. Grow.

4.8K Ratings
Open In App
title

Practice-Based Strategies: HER2-Positive Breast Cancer Case

Projects In Knowledge, Inc

0
Followers
0
Plays
Practice-Based Strategies: HER2-Positive Breast Cancer Case

Practice-Based Strategies: HER2-Positive Breast Cancer Case

Projects In Knowledge, Inc

0
Followers
0
Plays
OVERVIEWEPISODESYOU MAY ALSO LIKE

Details

About Us

This case-based online mentor workshop podcast focuses on practical strategies to manage metastatic breast cancer in your patients with HER2-positive disease. Presented by Reshma Mahtani, DO, it includes prerecorded Q & A from the proceedings of live audioconferences. This workshop podcast is a sequel to the data-driven webcast, "€œTargeting the Treatment of Metastatic Breast Cancer" and is a course in the Mentor Workshops: Practice-Based Strategies for Managing Metastatic Breast Cancer Patients curriculum program.

Latest Episodes

Part 8. Case Conclusion/Q A Part 2

Dr. Mahtani answers additional questions from the live audience including how protocols have evolved in recent years and the need for accurate HER2 testing.

5 min2011 OCT 28
Comments
Part 8. Case Conclusion/Q A Part 2

Part 7. Case Conclusion/Q A Part 1

Dr. Mahtani provides take-away messages from her case presentation on HER2-positive breast cancer, and then answers questions from the live audience. Topics include the use of trastuzumab and novel therapies in development for HER2-positive metastatic breast cancer.

4 min2011 OCT 28
Comments
Part 7. Case Conclusion/Q A Part 1

Part 6. Trastuzumab Beyond Progression

Dr. Mahtani discusses the use of trastuzumab in patients with HER2-positive metastatic breast cancer after progression on first-line trastuzumab.

1 min2011 OCT 28
Comments
Part 6. Trastuzumab Beyond Progression

Part 5. Capecitabine/Lapatinib Combination Therapy and Toxicity

Dr. Mahtani discusses toxicity associated with combination regimens that include capecitabine and lapatinib.

2 min2011 OCT 28
Comments
Part 5. Capecitabine/Lapatinib Combination Therapy and Toxicity

Part 4. Development of Brain Metastasis

Dr. Mahtani reviews the incidence of and factors associated with brain metastases in patients with HER2-positive metastatic breast cancer.

1 min2011 OCT 28
Comments
Part 4. Development of Brain Metastasis

Part 3. Novel Therapy T-DM1

Dr. Mahtani highlights the importance of novel therapies, such as TDM-1, in the treatment of HER2-positive metastatic breast cancer.

1 min2011 OCT 28
Comments
Part 3. Novel Therapy T-DM1

Part 2. Trastuzumab for Small Node Negative HER2+ Tumors

Dr. Mahtani discusses the role of trastuzumab in selected patients with small HER2-positive tumors.

4 min2011 OCT 28
Comments
Part 2. Trastuzumab for Small Node Negative HER2+ Tumors

Part 1. Case Presentation

Dr. Mahtani presents the case of a 44-year-old woman with a small HER2-positive tumor who progressed 2 years after initial mastectomy.

6 min2011 OCT 28
Comments
Part 1. Case Presentation
the END

Latest Episodes

Part 8. Case Conclusion/Q A Part 2

Dr. Mahtani answers additional questions from the live audience including how protocols have evolved in recent years and the need for accurate HER2 testing.

5 min2011 OCT 28
Comments
Part 8. Case Conclusion/Q A Part 2

Part 7. Case Conclusion/Q A Part 1

Dr. Mahtani provides take-away messages from her case presentation on HER2-positive breast cancer, and then answers questions from the live audience. Topics include the use of trastuzumab and novel therapies in development for HER2-positive metastatic breast cancer.

4 min2011 OCT 28
Comments
Part 7. Case Conclusion/Q A Part 1

Part 6. Trastuzumab Beyond Progression

Dr. Mahtani discusses the use of trastuzumab in patients with HER2-positive metastatic breast cancer after progression on first-line trastuzumab.

1 min2011 OCT 28
Comments
Part 6. Trastuzumab Beyond Progression

Part 5. Capecitabine/Lapatinib Combination Therapy and Toxicity

Dr. Mahtani discusses toxicity associated with combination regimens that include capecitabine and lapatinib.

2 min2011 OCT 28
Comments
Part 5. Capecitabine/Lapatinib Combination Therapy and Toxicity

Part 4. Development of Brain Metastasis

Dr. Mahtani reviews the incidence of and factors associated with brain metastases in patients with HER2-positive metastatic breast cancer.

1 min2011 OCT 28
Comments
Part 4. Development of Brain Metastasis

Part 3. Novel Therapy T-DM1

Dr. Mahtani highlights the importance of novel therapies, such as TDM-1, in the treatment of HER2-positive metastatic breast cancer.

1 min2011 OCT 28
Comments
Part 3. Novel Therapy T-DM1

Part 2. Trastuzumab for Small Node Negative HER2+ Tumors

Dr. Mahtani discusses the role of trastuzumab in selected patients with small HER2-positive tumors.

4 min2011 OCT 28
Comments
Part 2. Trastuzumab for Small Node Negative HER2+ Tumors

Part 1. Case Presentation

Dr. Mahtani presents the case of a 44-year-old woman with a small HER2-positive tumor who progressed 2 years after initial mastectomy.

6 min2011 OCT 28
Comments
Part 1. Case Presentation
the END
success toast
Welcome to Himalaya LearningClick below to download our app for better listening experience.Download App